Prof. Sahin is a doctor of medicine, immunologist and cancer researcher. His key focus is translating groundbreaking novel scientific ideas into medical innovations that help individual patients, an interest that was originally prompted by his experiences as a trained physician. His made key contributions in various fields of cancer immunotherapy covering the discovery of tumor associated cancer antigens, development of novel monoclonal antibodies for treatment of solid human cancers and various classes of RNA based immunotherapies. His team has pioneered the concept of individualized cancer immunotherapies and in particular the development of mRNA-based vaccines that are tailored to each patient´s cancer mutation profile. Ugur Sahin is Professor at the University Medical Center, Johannes Gutenberg-University, founder and managing scientific director of TRON and co-founder and CEO of BioNTech.
Michael Föhlings has been Managing Director (CFO) of the non-profit institute TRON GmbH in Mainz, Germany, since 2011 and has built up its financial and administrative organisation.
During his 30 years career in glass, steel and polymer industries, he has held diverse senior financial and general management functions in British, Anglo-Dutch and Swiss multinational companies. During that time he was also a member of company boards in Germany, Italy, Spain, the United States and China.
He is a practitioner in the financial management of international multi-site groups operating in manufacturing business environments and also gained practical experience in the restructuring and repositioning of companies in Germany, Spain and the US. He built up a number of financial and administrative organisations from scratch before he joined TRON.
Michael Föhlings studied business administration, business and labour law and real estate management at Westfälische Wilhelms-University Münster, EBS European Business School, Schloss Reichartshausen and IMD, Lausanne, Switzerland. He holds Diplomas in Business Administration and Real Estate Management.